Integer Holdings Corporation (ITGR) Stock Price
ITGRStock
$126.70+22.87%52W
Market Cap$4.31B
P/E41.90x
PEG Ratio2.81
Div yield—
Beta0.59
ITGR Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)33.05%
Price vs S&P 500 (4W)1.58%
PEG Ratio2.81
VGM Score57.73
P/E Ratio (Annual)41.90x
ITGR Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | $1.38 | $1.60 | +15.80%(+$0.22) | |
| Q1 2026 | $1.19 | $1.20 | +1.13%(+$0.01) | |
| Q4 2025 | $1.70 | $1.76 | +3.62%(+$0.06) | |
| Q3 2025 | $1.68 | $1.79 | +6.83%(+$0.11) | |
| Q2 2025 | $1.55 | $1.55 | -0.05%(-$0.00) |
ITGR Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
3.82
3.82
3.82
2.67
Industry Peers — Electromedical Equipment(31)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|---|---|---|
ITGRInteger Holdings Corporation | C | C | A | 2.3x | 11.6% | 26.1% | 9.7% | $126.70 |
| MDTMedtronic plc | B | C | B | 3.2x | 3.8% | 65.7% | 18.1% | $94.75 |
| LIVNLivaNova PLC Ordinary Shares | C | B | B | 2.9x | 8.2% | 68.1% | 12.5% | $77.58 |
| TMDXTransMedics Group, Inc. Common Stock | C | B | D | 3.7x | 88.2% | 58.7% | 12.2% | $70.78 |
| AXGNAxogen, Inc. Common Stock | F | B | B | 8.1x | 14.9% | 74.6% | -11.8% | $34.62 |
| BLFSBioLife Solutions Inc. | F | C | A | 18.4x | 14.9% | 63.9% | 2.9% | $38.61 |
| CNMDCONMED Corporation | B | C | B | 1.0x | 9.8% | 55.8% | 8.0% | $46.72 |
| CBLLCeriBell, Inc. Common Stock | F | A | A | 9.4x | — | 88.9% | -68.6% | $25.04 |
| INMDInMode Ltd. Ordinary Shares | A | D | C | 2.2x | 12.4% | 76.5% | 18.5% | $14.16 |
| CVCapsoVision, Inc. Common Stock | F | D | B | 25.0x | — | 50.9% | -217.1% | $6.53 |
| ELMDElectromed, Inc. | C | B | C | 3.1x | 15.6% | 78.5% | 18.8% | $27.42 |
About Integer Holdings Corporation
Integer Holdings Corp manufactures specialized medical device components for original equipment manufacturers across the medical industry. The company operates three primary business lines: Cardio & Vascular, Cardiac Rhythm Management & Neuromodulation, and Other Markets. Integer generates the majority of its revenue in the United States, with additional operations in Ireland, Puerto Rico, Costa Rica, and other international markets.